Cite
HARVARD Citation
Sheng, X. et al. (2023). Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT). European journal of cancer. pp. 205-215. [Online].